Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

J&J in $400 Million Settlement Over Faulty Hip Replacements

  • Post author:Sam
  • Post published:January 11, 2019
  • Post category:The GMP Letter

Johnson & Johnson agreed to settle consumer complaints of defective artificial hips for more than $400 million. Source: The GMP Letter

Continue ReadingJ&J in $400 Million Settlement Over Faulty Hip Replacements

TGA Offers Guidance on Regulating Software as a Medical Device

  • Post author:Sam
  • Post published:January 11, 2019
  • Post category:The GMP Letter

Australia’s Therapeutic Goods Administration is reviewing how it regulates software as a medical device (SaMD) and has issued guidance on its latest thinking. Source: The GMP Letter

Continue ReadingTGA Offers Guidance on Regulating Software as a Medical Device

FDA Releases Draft Guidances on Blood Glucose Monitors

  • Post author:Sam
  • Post published:December 6, 2018
  • Post category:The GMP Letter

The FDA issued separate draft guidances on blood glucose monitors used in health care settings and on over-the-counter products used in the home. When finalized, they will replace guidances the…

Continue ReadingFDA Releases Draft Guidances on Blood Glucose Monitors

FDA Reconsiders Electronic Labeling for Certain Devices

  • Post author:Sam
  • Post published:December 6, 2018
  • Post category:The GMP Letter

The FDA has withdrawn a proposed rule that would have required manufacturers to submit labels and package inserts in electronic format for certain home-use medical devices. Source: The GMP Letter

Continue ReadingFDA Reconsiders Electronic Labeling for Certain Devices

FDA Issues Updates on Overheating Problems in MR-Guided Lasers

  • Post author:Sam
  • Post published:December 6, 2018
  • Post category:The GMP Letter

Monteris is releasing a new version of its NeuroBlate probe to address a problem with overheating of its magnetic resonance-guided laser thermal therapy device. The new probe is equipped with…

Continue ReadingFDA Issues Updates on Overheating Problems in MR-Guided Lasers

FDA Issues Updated Medical Device Safety Action Plan

  • Post author:Sam
  • Post published:December 6, 2018
  • Post category:The GMP Letter

The FDA plans to continue building out its National Evaluation System for health Technology (NEST) and it is increasing its focus on device therapies unique to women, Commissioner Scott Gottlieb…

Continue ReadingFDA Issues Updated Medical Device Safety Action Plan

483 Roundup: FDA Cites Firms for Quality, Risk Analysis and SOPs

  • Post author:Sam
  • Post published:December 6, 2018
  • Post category:The GMP Letter

The FDA flagged seven devicemakers for quality system and other failures observed during inspections. Source: The GMP Letter

Continue Reading483 Roundup: FDA Cites Firms for Quality, Risk Analysis and SOPs

Warning Letter Roundup: Three Firms Cited for Adulterated Devices

  • Post author:Sam
  • Post published:December 6, 2018
  • Post category:The GMP Letter

The FDA hit three foreign device manufacturers with warning letters, calling the firms out for quality system violations that led to adulterated products. Source: The GMP Letter

Continue ReadingWarning Letter Roundup: Three Firms Cited for Adulterated Devices

CDRH Posts New Timeline, Update on Medical Device Testing Accreditation Pilot

  • Post author:Sam
  • Post published:December 6, 2018
  • Post category:The GMP Letter

The FDA posted an update on its Accreditation Scheme for Conformity Assessment (ASCA) pilot, which aims to streamline conformity assessments for medical device submissions that meet yet-to-be-announced standards. Source: The…

Continue ReadingCDRH Posts New Timeline, Update on Medical Device Testing Accreditation Pilot

FDA Extends UDI Deadlines Another Two Years for Class I, Unclassified Devices

  • Post author:Sam
  • Post published:December 6, 2018
  • Post category:The GMP Letter

The FDA said it will allow device manufacturers of Class I and unclassified devices another two years to comply with its unique device identification system requirements, which are being phased…

Continue ReadingFDA Extends UDI Deadlines Another Two Years for Class I, Unclassified Devices
  • Go to the previous page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 44
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.